Teva CEO Schultz To Sign On For Another Year

Schultz Set For At Least Six Years As Teva’s CEO

 
• By Dean Rudge
  
Meeting_Room
Teva's board of directors wants to keep CEO Kåre Schultz on board until at least 2023 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Leadership

More from Generics Bulletin